459 related articles for article (PubMed ID: 15131028)
1. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
[TBL] [Abstract][Full Text] [Related]
2. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
Mey V; Giovannetti E; De Braud F; Nannizzi S; Curigliano G; Verweij F; De Cobelli O; Pece S; Del Tacca M; Danesi R
Br J Cancer; 2006 Aug; 95(3):289-97. PubMed ID: 16868547
[TBL] [Abstract][Full Text] [Related]
3. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells.
Giovannetti E; Mey V; Nannizzi S; Pasqualetti G; Marini L; Del Tacca M; Danesi R
Mol Pharmacol; 2005 Jul; 68(1):110-8. PubMed ID: 15795320
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
[TBL] [Abstract][Full Text] [Related]
5. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
[TBL] [Abstract][Full Text] [Related]
6. [Effects of gemcitabine and pemetrexed on the proliferation of pancreatic cancer cell lines BXPC-3 and PANC-1 in vitro].
Zhu ZX; Zhang WM; Jia G; Zhou J
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jan; 30(1):149-52. PubMed ID: 20118008
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
8. The pemetrexed/gemcitabine combination in pancreatic cancer.
Kindler HL
Cancer; 2002 Aug; 95(4 Suppl):928-32. PubMed ID: 12209673
[TBL] [Abstract][Full Text] [Related]
9. Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells.
Giovannetti E; Leon LG; Bertini S; Macchia M; Minutolo F; Funel N; Alecci C; Giancola F; Danesi R; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):419-26. PubMed ID: 20544530
[TBL] [Abstract][Full Text] [Related]
10. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
[TBL] [Abstract][Full Text] [Related]
11. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
Nagai S; Takenaka K; Sonobe M; Wada H; Tanaka F
Chemotherapy; 2008; 54(3):166-75. PubMed ID: 18560222
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
[TBL] [Abstract][Full Text] [Related]
13. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
Funamizu N; Okamoto A; Kamata Y; Misawa T; Uwagawa T; Gocho T; Yanaga K; Manome Y
Oncol Rep; 2010 Feb; 23(2):471-5. PubMed ID: 20043109
[TBL] [Abstract][Full Text] [Related]
14. Synergistic combination of gemcitabine and dietary molecule induces apoptosis in pancreatic cancer cells and down regulates PKM2 expression.
Pandita A; Kumar B; Manvati S; Vaishnavi S; Singh SK; Bamezai RN
PLoS One; 2014; 9(9):e107154. PubMed ID: 25197966
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
16. Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines.
Si S; Liao Q; Zhao YP; Hu Y; Zhang Q; You LL
Chin Med J (Engl); 2011 Feb; 124(3):419-22. PubMed ID: 21362344
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
[TBL] [Abstract][Full Text] [Related]
18. A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.
Mercalli A; Sordi V; Formicola R; Dandrea M; Beghelli S; Scarpa A; Di Carlo V; Reni M; Piemonti L
Br J Cancer; 2007 May; 96(9):1358-67. PubMed ID: 17426706
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed in pancreatic cancer.
Kindler HL
Semin Oncol; 2002 Dec; 29(6 Suppl 18):49-53. PubMed ID: 12571811
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth.
Vernejoul F; Ghénassia L; Souque A; Lulka H; Drocourt D; Cordelier P; Pradayrol L; Pyronnet S; Buscail L; Tiraby G
Mol Ther; 2006 Dec; 14(6):758-67. PubMed ID: 17000136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
